The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer

The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is rec...

Full description

Bibliographic Details
Main Author: K. E. Borisov
Format: Article
Language:Russian
Published: ABV-press 2014-07-01
Series:Opuholi Ženskoj Reproduktivnoj Sistemy
Subjects:
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/88